Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche’s Master Plan: Perjeta Gains Early Breast Cancer Approval, Late-Stage Kadcyla Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Perjeta’s approval in neoadjuvant breast cancer signals paradigm change as first approval under new pathway. Meanwhile, antibody-drug conjugate Kadcyla proves its worth in heavily pretreated, advanced breast cancer.

You may also be interested in...



Pivotal Data Put Roche's Kadcyla In Position For Earlier Breast Cancer

KATHERINE supports filings for earlier use of Kadyla in adjuvant setting of breast cancer.

Which Biopharmas Are Best Positioned For Five-Year Growth?

Morningstar expects 229% revenue growth during the 2015-2020 period for BioMarin, far stronger than larger competitors. Virology powerhouse Gilead is the only one of the 20 largest biopharmas expected to face a decline in revenue over the period.

Cancer Trial Endpoints: Minimal Residual Disease Eyed As Surrogate

More work needs to be done to validate MRD as predictive of clinical outcomes in hematological malignancies before it can be used as the basis for accelerated approval, FDA and other stakeholders say.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel